CN109315770A - Anti-oxidant dietary supplements and its production method - Google Patents
Anti-oxidant dietary supplements and its production method Download PDFInfo
- Publication number
- CN109315770A CN109315770A CN201811091498.1A CN201811091498A CN109315770A CN 109315770 A CN109315770 A CN 109315770A CN 201811091498 A CN201811091498 A CN 201811091498A CN 109315770 A CN109315770 A CN 109315770A
- Authority
- CN
- China
- Prior art keywords
- parts
- oxidant
- mixed
- weight
- soft capsule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003963 antioxidant agent Substances 0.000 title claims abstract description 34
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 34
- 235000006708 antioxidants Nutrition 0.000 title claims abstract description 34
- 235000015872 dietary supplement Nutrition 0.000 title claims abstract description 23
- 238000004519 manufacturing process Methods 0.000 title abstract description 6
- 229940038487 grape extract Drugs 0.000 claims abstract description 31
- 241000168517 Haematococcus lacustris Species 0.000 claims abstract description 24
- 239000007901 soft capsule Substances 0.000 claims abstract description 23
- 239000000463 material Substances 0.000 claims abstract description 10
- 239000000047 product Substances 0.000 claims abstract description 10
- 241000219095 Vitis Species 0.000 claims abstract description 6
- 235000009754 Vitis X bourquina Nutrition 0.000 claims abstract description 6
- 235000012333 Vitis X labruscana Nutrition 0.000 claims abstract description 6
- 235000014787 Vitis vinifera Nutrition 0.000 claims abstract description 6
- 239000000284 extract Substances 0.000 claims abstract description 5
- 150000008442 polyphenolic compounds Chemical class 0.000 claims abstract description 4
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 39
- 239000000203 mixture Substances 0.000 claims description 26
- 239000003292 glue Substances 0.000 claims description 21
- 239000007788 liquid Substances 0.000 claims description 17
- 239000001993 wax Substances 0.000 claims description 16
- 235000013871 bee wax Nutrition 0.000 claims description 15
- 241000229143 Hippophae Species 0.000 claims description 14
- 235000003145 Hippophae rhamnoides Nutrition 0.000 claims description 14
- 239000012166 beeswax Substances 0.000 claims description 14
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 14
- 239000008213 purified water Substances 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 108010010803 Gelatin Proteins 0.000 claims description 13
- 238000011049 filling Methods 0.000 claims description 13
- 229920000159 gelatin Polymers 0.000 claims description 13
- 239000008273 gelatin Substances 0.000 claims description 13
- 235000019322 gelatine Nutrition 0.000 claims description 13
- 235000011852 gelatine desserts Nutrition 0.000 claims description 13
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 9
- 238000010438 heat treatment Methods 0.000 claims description 8
- 239000008188 pellet Substances 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 7
- 235000012054 meals Nutrition 0.000 claims description 7
- 239000013589 supplement Substances 0.000 claims description 7
- 238000007493 shaping process Methods 0.000 claims description 4
- 238000000227 grinding Methods 0.000 claims description 3
- 238000007689 inspection Methods 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 2
- 235000009508 confectionery Nutrition 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 2
- 229930003427 Vitamin E Natural products 0.000 claims 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 235000019165 vitamin E Nutrition 0.000 claims 1
- 229940046009 vitamin E Drugs 0.000 claims 1
- 239000011709 vitamin E Substances 0.000 claims 1
- 230000003064 anti-oxidating effect Effects 0.000 abstract description 8
- 230000036541 health Effects 0.000 abstract description 7
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 150000003254 radicals Chemical class 0.000 description 39
- 230000000694 effects Effects 0.000 description 23
- 230000006378 damage Effects 0.000 description 22
- 238000007254 oxidation reaction Methods 0.000 description 21
- 230000003647 oxidation Effects 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 13
- 230000006870 function Effects 0.000 description 11
- 229910052760 oxygen Inorganic materials 0.000 description 9
- 239000001301 oxygen Substances 0.000 description 9
- -1 oxygen radical Chemical class 0.000 description 9
- 230000000302 ischemic effect Effects 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 201000001320 Atherosclerosis Diseases 0.000 description 6
- 208000024172 Cardiovascular disease Diseases 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 102000007330 LDL Lipoproteins Human genes 0.000 description 5
- 108010007622 LDL Lipoproteins Proteins 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 230000004792 oxidative damage Effects 0.000 description 5
- 102000006587 Glutathione peroxidase Human genes 0.000 description 4
- 108700016172 Glutathione peroxidases Proteins 0.000 description 4
- 208000034189 Sclerosis Diseases 0.000 description 4
- 102000019197 Superoxide Dismutase Human genes 0.000 description 4
- 108010012715 Superoxide dismutase Proteins 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 239000000262 estrogen Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000168525 Haematococcus Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 206010063837 Reperfusion injury Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000000711 cancerogenic effect Effects 0.000 description 3
- 231100000315 carcinogenic Toxicity 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 210000001508 eye Anatomy 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000003859 lipid peroxidation Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
- 201000006474 Brain Ischemia Diseases 0.000 description 2
- 208000002177 Cataract Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010029164 Nephrotic syndrome Diseases 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- 230000005907 cancer growth Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000000695 crystalline len Anatomy 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 208000009928 nephrosis Diseases 0.000 description 2
- 231100001027 nephrosis Toxicity 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 238000005502 peroxidation Methods 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical group OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 108010013043 Acetylesterase Proteins 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 206010001580 Albuminuria Diseases 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 241000195627 Chlamydomonadales Species 0.000 description 1
- 206010008570 Chloasma Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010011033 Corneal oedema Diseases 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 208000001034 Frostbite Diseases 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 241000192041 Micrococcus Species 0.000 description 1
- 102000010909 Monoamine Oxidase Human genes 0.000 description 1
- 108010062431 Monoamine oxidase Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 102000003896 Myeloperoxidases Human genes 0.000 description 1
- 108090000235 Myeloperoxidases Proteins 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 239000005700 Putrescine Substances 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000235342 Saccharomycetes Species 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 108060008539 Transglutaminase Proteins 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000002225 anti-radical effect Effects 0.000 description 1
- 230000007234 antiinflammatory process Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 235000013793 astaxanthin Nutrition 0.000 description 1
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 1
- 229940022405 astaxanthin Drugs 0.000 description 1
- 239000001168 astaxanthin Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000008952 bacterial invasion Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000001058 brown pigment Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008568 cell cell communication Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000008809 cell oxidative stress Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 229940124443 chemopreventive agent Drugs 0.000 description 1
- 239000012627 chemopreventive agent Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 201000004778 corneal edema Diseases 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 201000010251 cutis laxa Diseases 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 210000000585 glomerular basement membrane Anatomy 0.000 description 1
- 210000001707 glomerular endothelial cell Anatomy 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 210000004493 neutrocyte Anatomy 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 108091008695 photoreceptors Proteins 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000011814 protection agent Substances 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 229940079877 pyrogallol Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000007348 radical reaction Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008327 renal blood flow Effects 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 102000003601 transglutaminase Human genes 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 125000005314 unsaturated fatty acid group Chemical group 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Present invention relates particularly to a kind of anti-oxidant dietary supplements and its production methods, and anti-oxidant dietary supplements is by weight, comprising: 6~12 parts of grape extract；4~8 parts of haematococcus pluvialis；Remaining is soft capsule prepared product；The grape extract refers to extracts isolated polyphenols from Grape Skin and/or seed；The soft capsule prepared product is for material needed for dietary supplements is prepared into soft capsule.Anti-oxidant dietary supplements provided by the present application, due to not only having good anti-oxidation function comprising grape extract and haematococcus pluvialis, moreover it is possible to a lot of other health-care efficacies is played, is taken for a long time, it is highly beneficial to health.
Description
Technical field
The present invention relates to dietary supplements technical field more particularly to a kind of anti-oxidant dietary supplements and its producer
Method.
Background technique
Cell generates a variety of biochemical reactions in normal metabolic processes, forms centre in this reaction process
Metabolin-free radical.Under normal circumstances, it is flat to be always at the dynamic for constantly generating and constantly eliminating for the intracorporal free radical of people
In weighing apparatus, if free radical generates excessively or removing is very few, the injury to cell tissue will result in.Each cell of people daily may be used
By 103~104Free radical attack makes the various substances for constituting cell tissue, such as lipid, carbohydrate, protein, deoxyribose core
All macromolecular substances such as acid, occur each kinds of oxidation reaction, cause the oxidative damages such as denaturation, crosslinking, fracture, and then cause thin
The lesion of the destruction of born of the same parents' structure and function and the damage of body tissue and organ.
There is important relation with a variety of diseases in oxidation:
Oxidation and cardiovascular and cerebrovascular disease: oxygen radical causes lipid peroxidation, leads to atherosclerosis, this is to lead to the heart
The main reason for cranial vascular disease.The artery sclerosis of atherosclerosis namely our common names, when the intracorporal low density lipoprotein of people
Albumen runs into free radical, is exactly the beginning of artery sclerosis.In other words, really form atherosclerosis is " by free radical
Oxided low-density lipoprotein ", cell membrane cause platelet aggregation by free-radical oxidation, this is that headstroke, myocardial infarction are formed
The first step.
Oxidation and diabetes: the β cell meeting excreting insulin in pancreas helps the glucose in blood to enter in cell,
It is converted into energy required for organizational operation, or extra sugar is stored at liver, in muscle or fat cell.Once β cell
By free-radical oxidation, and by free radical attack accumulation to it is a certain amount of when, β cell is to lose the ability of excreting insulin to be formed
Diabetes.Meanwhile free radical can promote model induced by alloxan insulin-dependent diabetes mellitus.
Oxidation and weight perfusion injury after ischemic: the main reason for tissue damage caused by ischemic is fatal disease, it is all
Such as coronary sclerosis and apoplexy.But there are many evidence explanation, only ischemic is also not enough to lead to tissue damage, but in ischemic
Restore just to damage when blood supply (being both perfused) again suddenly again after a period of time.Capilary caused by ischemic tissue is perfused again when and
Mainly as caused by oxyradical, this is proved obtained in a variety of organs for the damage of organa parenchymatosum.In traumatic body
Gram, surgery, organ transplant, burn, the blood circulation disorders such as frostbite and thrombus when, perfusion injury after ischemic can all occur.?
There is the antioxidant reductase synthesis capability for removing free radical obstacle occurs, thus after exacerbating free radical to ischemic in ischemic tissue
The damage of weight perfused tissue
Oxidation and cancer: a normal cell occurs canceration and is subjected to induce and promote two stages, and here it is two steps
Carcinogenic theory.Induction stage and Relationship between Free Radical are close.The Peroxidation Product that Free Radical is generated in lipid can it is carcinogenic again
Energy mutagenesis, the carcinogenic and mechanism of mutagenesis on a molecular scale is identical.Promote the canceration stage also related with free radical, promotees
Cancer ability is parallel with the ability that it is generated free radicals in chemotherapy process, since the toxicity of drug leads to intracellular generate largely
Free radical, this often causes bone marrow injury, oligoleukocythemia, chemotherapy is caused to slow down, and dose is reduced at chemotherapy is stopped, if making
Agent is understood with free radical, then can prevent marrow from further by the destruction of oxygen radical, accelerating the recovery of marrow and leucocyte amount, having
Conducive to the continuation of chemotherapy, it is seen that in order to which pre- anti-cancer and treating cancer must all move removing free radical.
Oxidation and inflammation: when having virus or bacterial invasion body, it is outer to eliminate that leucocyte can manufacture a large amount of free radical
The germ come, but excessive free radical, other than phagocytic virus and bacterium, also attack leucocyte itself causes its mortality,
As a result cause lysosomal enzyme it is a large amount of release and further kill or kill tissue phase born of the same parents, cause bone, cartilage destruction and cause
Inflammation and arthritis injure neighbouring group group born of the same parents, deteriorate inflammation symptom.It can be seen that inflammatory process and free radical have closely
Relationship.There is scientist to think that free radical induces arthritic reason and is to result in the degradation of hyaluronic acid, because of hyaluronic acid
It is the main component of high viscosity joint lubrication liquid
Oxidation and eye disease: eyes are the photoreceptors of humans and animals one, senile eyes aging (especially cataract) with
Radical reaction is related.Research shows that the elderly makes free radical scavenger in augen due to the aging of whole body body
Content and activity reduce, and lead to the low imperial ability decline encroached on free radical, the cause of cataract and development and free radical are to view
The damage of nethike embrane causes the destruction of lens tissue related.Cornea is caused endothelial cell to crack by free radical invasion, cell-permeant
There is obstacle in sexual function, causes corneal edema.Free radical can generate direct damage and be destroyed to crystalline lens.
Oxidation and color spot: oxygen radical decomposes collagen and elastin laminin, cutis laxa, wrinkle occurs while can be with
Unsaturated fatty acid forms lipoid brown pigment under oxide skin, and sunburn, chloasma, senile plaque etc. occurs in skin.
Oxidation and Parkinson's disease: free radical destroys brain cell so that caused by neurotransmitter dopamine lacks, DOPA
Amine is and moves related neurotransmitter, and shortage dopamine will cause hand and not tremble independently, muscular paralysis, slow movement
Etc. clinical symptoms.
Oxidation and kidney trouble: the blood flow that the mankind pass through kidney is about a quarter of cardiac output, therefore kidney
It is one of the vitals that oxygen radical is obtained by blood.By the releasable a large amount of oxygen radicals of the inflammatory cell that is infiltrated in kidney,
And it can promote the oxygen radical of neutrophil leucocyte and myeloperoxidase enzymatic formation initiation renal damage.In glomerular endothelial cells
When ischemiareperfusion occurs, the oxygen radical that renal cells generate is sharply increased.
Oxidation and disease of digestive tract: the oxyradical of alimentary system mainly as caused by neutrophil,
Alimentary canal category mucomembranous immune system is the very fierce place of biological precursor reactant, and neutrophil is easy to thin to mucous membrane
The infiltration of born of the same parents increases, and the injury of oxygen radical is caused to aggravate.
Oxidation and hepatopathy: liver is maximum digestion body of gland in human body, and the function of central chemical is played in human body,
It is the extremely active important organ of body metabolism, therefore is easier the attack by free radical, leads to liver plasma membrane lipid peroxidation,
To influence glutathione enzyme system and various microelements related with free radical enzyme system.
Therefore, human body anti-oxidation function is improved, the health to human body is highly beneficial, in this regard, the application provides one
Kind uses the anti-oxidant dietary supplements safe, without side-effects, therapeutic effect is good.
Summary of the invention
The purpose of the present invention is to provide a kind of anti-oxidant meal supplements good using safe, without side-effects, therapeutic effect
Agent and its production method.
To achieve the above object, the present invention provides a kind of anti-oxidant dietary supplements, comprising:
6~12 parts of grape extract；4~8 parts of haematococcus pluvialis；Remaining is soft capsule prepared product；
Wherein, the grape extract refers to extracts isolated polyphenols from Grape Skin and/or seed；The flexible glue
Capsule prepared product is for material needed for dietary supplements is prepared into soft capsule.
In the above-mentioned technical solutions, further, the soft capsule prepared product includes soft capsule content and soft capsule
Prepare auxiliary material；The parts by weight of the soft capsule content are 25~40 parts；The soft capsule prepare auxiliary material parts by weight be 450~
580 parts.
In the above-mentioned technical solutions, further, the soft capsule content includes natural VE, beeswax and sea-buckthorn
Oil, the parts by weight of the natural VE are 1.6 parts, and the parts by weight of the beeswax are 1.6 parts, the parts by weight of the Seabuckthorn Oil
It is 24 parts；It includes gelatin, purified water, glycerol and red ferric oxide that the soft capsule, which prepares auxiliary material, and the parts by weight of the gelatin are 200
Part, the parts by weight of the purified water are 200 parts, and the parts by weight of the glycerol are 80 parts, and the parts by weight of the red ferric oxide are 2
Part.
In the above-mentioned technical solutions, further, by weight, comprising: 8 parts of grape extract；Haematococcus pluvialis 4.8
Part；1.6 parts of natural VE；1.6 parts of beeswax；24 parts of Seabuckthorn Oil；200 parts of gelatin；200 parts of purified water；80 parts of glycerol；Red oxygen
Change 2 parts of iron.
In addition, the application provides a kind of anti-oxidant meal supplement agent and process for producing same, comprising:
Grape extract and haematococcus pluvialis are mixed, the first mixture is prepared into；
Natural VE, beeswax and Seabuckthorn Oil are mixed and are processed into oily wax liquor；
First mixture is mixed with oily wax liquor and is processed into filling liquid；
Gelatin, purified water, glycerol and red ferric oxide are mixed and are processed into glue；
Capsule pellet press is by filling liquid and glue machine-shaping.
In the above-mentioned technical solutions, further, natural VE, beeswax and Seabuckthorn Oil are mixed and is processed into oily wax
Liquid includes:
Natural VE and Seabuckthorn Oil are mixed and heated (heating temperature is 75-85 DEG C), are prepared into the second mixture；It will
Second mixture and beeswax are mixed and heated (heating temperature is 70-80 DEG C), are prepared into oily wax liquor；Cooling (the 40-50 of oily wax liquor
DEG C) mixed afterwards with the first mixture.
In the above-mentioned technical solutions, further, the first mixture is mixed with oily wax liquor and is processed into filling liquid and include:
First mixture is mixed with oily wax liquor and is stirred in material-compound tank；It is ground after stirring；De-bubbled after grinding；It is prepared into
Filling liquid.
In the above-mentioned technical solutions, further, gelatin, purified water, glycerol and red ferric oxide are mixed and processes plastic
Liquid includes:
Purified water and glycerol are mixed and heated (heating temperature is 70-80 DEG C), are prepared into third mixture；
Gelatin, red ferric oxide and third mixture are mixed and stirred for, realizationization glue；
De-bubbled is prepared into glue.
In the above-mentioned technical solutions, further, filling liquid and glue machine-shaping are included: capsule pressure by capsule pellet press
Pellet is made in filling liquid and glue by ball machine；Stand setting；Cleaning；It is dry；Quality inspection.
Anti-oxidant dietary supplements provided by the present application, has a good anti-oxidation function, efficacy stability, and without bad anti-
It answers.
Specific embodiment
In order to more clearly state the present invention, the present invention is further described.
Anti-oxidant dietary supplements provided by the present application weighs 2 kilograms of grape extract by formula rate, haematococcus pluvialis
1.2 kilograms, 0.4 kilogram of natural VE, 6 kilograms of Seabuckthorn Oil, 0.4 kilogram of beeswax, then take 20 kilograms of glycerol, purified water 50,000
Gram, 50 kilograms of gelatin, 0.5 kilogram of red ferric oxide.Prepared according to the following process:
Grape extract and haematococcus pluvialis are mixed, sieving (80 mesh) is prepared into the first mixture respectively.
Natural VE and Seabuckthorn Oil are mixed and heated, and heating temperature is 80 DEG C, are prepared into the second mixture；By second
Mixture is mixed and heated with beeswax, and heating temperature is 70-80 DEG C, is dissolved beeswax all, is prepared into oily wax liquor.
Oily wax liquor is cooled to 40-50 DEG C, mixes afterwards with the first mixture, and 30min is stirred in material-compound tank, keeps mixing equal
It is even.Then, it crosses colloidal grinding 3 times；De-bubbled vacuumizes, vacuum degree is maintained at -0.06Mpa；It is prepared into filling liquid.
Purified water and glycerol after mixing, are heated in changing glue tank, temperature is maintained at 70 DEG C~80 DEG C, is prepared into
Third mixture；Gelatin, red ferric oxide and third mixture are mixed and stirred for, realizationization glue；De-bubbled vacuumizes, very
Reciprocal of duty cycle is maintained at -0.06Mpa；It is prepared into glue.Glue filters (100 mesh), saves at 50 DEG C~60 DEG C.
Glue and filling liquid set automatic rotary soft capsule pellet press compacting pelletization, and specification is 0.5g/；20 DEG C~24
DEG C, in the environment of relative humidity 30%~40%, stand 4h, setting；It is cleaned with 95% edible alcohol；24 DEG C~28 DEG C, relatively
Humidity 20%~30%, drying is for 24 hours；Quality inspection removes non-conformality ball.
This dietary supplements 19200 qualified soft capsules are finally made after above-mentioned production technology.
Instructions of taking is to be taken twice daily, two every time.For verification the verifying results, anti-oxidation function human experiment has been carried out
Experiment.
This experiment try trencherman's standard: male or female, the age 18-65 years old, physical condition was good, without obvious brain, the heart, liver, lung,
Kidney, Hematological Diseases, no Long-term taking medicine history volunteer the tested crowd for guaranteeing cooperation.
This experimental evaluation index and result judgement: lipid oxidation products, superoxide dismutase, glutathione peroxidase
Binomial is positive in three indexs of enzyme, and on body health without influence, can determine that the given the test agent has oxidation resistant effect.It is every
Index on-test and at the end of respectively detection it is primary.
Test method: it is 52 that this experiment, which participates in test-meal number, daily this dietary supplements 2 times, 2 tablets each time,
Taking the period is continuous 180 days, and primary work, diet are constant during test.
Test result: after subject takes tested material 180 days, the results showed that serum superoxide dismutases, paddy after test-meal
The sweet peptide peroxidase activity of Guang improves 9.64%, 8.91% before relatively testing respectively, the test of serum lipids oxidation product is dropped earlier above
Low 4.05%, wherein compared with before test, difference has aobvious for serum superoxide dismutases, glutathione peroxidase activity
Work property (P < 0.05).The above results show that this dietary supplements has anti-oxidation function.
Anti-oxidant dietary supplements provided by the present application is good due to having comprising grape extract and haematococcus pluvialis
Anti-oxidant and healthcare function.
Grape extract is that isolated a kind of polyphenols, specially resveratrol are extracted from Grape Skin, seed；
Grape extract is pure natural substance, is one of the most efficient antioxidant of plant origin found so far, is the chemistry of tumour
Prophylactic, and to platelet aggregation is reduced, prevent and treat the chemopreventive agent of atherosclerosis, cardiovascular and cerebrovascular disease.
Have plurality of health care functions:
1, antitumor action；Grape extract, which has, inhibits growth of cancer cells effect, to grape extract anti-tumor activity machine
The result of study of system shows that grape extract all shows antitumor efficacy in tumour promotion, promotion and development three phases.Pass through
Inhibit cytochromes enzyme, induction detoxication enzyme, inhibits cyclooxygenase, inhibits protein kinase, antagonising oestrogen and change autocrine raw
Long regulatory factor, induction tumor cell differentiation and rush Apoptosis etc. inhibit growth of cancer cells effect to realize.
2, to the effect of cardiovascular system；With cardiovascular disease incidence rate cumulative year after year, the angiocarpy of grape extract
Protective effect has become research hotspot, can be by reducing Myocardial Ischemia Reperfusion Injury, inhibiting atherosclerosis and blood
The formation of bolt, anti-inflammatory, anti-oxidant, vasodilator, etc. play cardiovascular protective effect.
3, anti-oxidant, anti-radical action；Grape extract is natural plant antioxidant, plays oxidation resistant effect
Mechanism is mainly removed or free radical is inhibited to generate, anti-lipid peroxidation, the anti-oxidant related enzyme activity of adjusting etc..In recent years,
People to grape extract it is anti-oxidant, remove free radical physiological function extensive concern because these physiological metabolisms are related to
Such as atherosclerosis, senile dementia, the virus hepatitis many physiological maladies closely related with human health.
4, anti-inflammatory, antibacterial acts on；Grape extract is to staphylococcus aureus, micrococcus catarrhalis, Escherichia coli, Pseudomonas aeruginosa
There is stronger inhibiting effect by inhibiting effect, and to orphan virus, herpes simplex virus and enterovirus, Coxsack A, B group.Together
When, grape extract is by reducing sticking for blood platelet, and the activity of change blood platelet achievees the effect that anti-inflammatory in antiinflammatory processes.
5, anti-aging effects；The study found that grape extract can activate acetylase, increase the service life of saccharomycete, this
It was found that exciting people to the upsurge of grape extract research on anti-senescence.Up to the present, there is research it has been confirmed that grape extracts
Object has effects that extend yeast, nematode, drosophila and low fish service life.
6, estrogen action；Grape extract has estrogen-like action in vivo, it is to estrogen-dependent tumor (packet
Include breast cancer, prostate cancer, carcinoma of endometrium and oophoroma etc.) by apparent prevention effect, it can also make up premenopausal and postmenopausal women
Internal estrogen secretion is insufficient, to reduce the risk for suffering from osteoporosis.
7, hepatoprotective effect；Grape extract has protection liver, the effect for inhibiting lipoids peroxide to accumulate in liver.
Grape extract can reduce nitric oxide caused by pyrogallol and malonaldehyde increases, and inhibit activities of nitric oxide synthase, rise
High superoxidase and activity of glutathione peroxidase, reduce the consumption of reductive glutathione, to protect liver cell.
8, protection nervous system grape extract Mechanism of neuroprotective effect mainly reduces brain cell oxidative stress, reduces
Cerebral ischemia radical damage reduces free radical and lipid peroxidation, increases superoxide dismutase and glutathione peroxidase
Enzymatic activity inhibits activity of monoamine oxidase in brain.Grape extract is also to Brain Ischemia-reperfusion Injury, Parkinson, epilepsy, ridge
The nervous system diseases such as marrow damage also have protection and therapeutic effect.
Haematococcus pluvialis, and it is called the raw haematococcus in lake, it is a kind of generally existing green alga, belongs to volvocales, haematococcus
Section, carrotene in the sea of being known as is a kind of natural antioxidant, and content astaxanthin is 1.5%~3.0%.And
And have plurality of health care functions:
1, the protective effect of eye and central nervous system；Human retina and central nervous system (brain) are rich in unsaturated lipid
Fat acid, therefore, the free radical for aoxidizing generation is easy to bring it about peroxide injury.Some researches show that haematococcus pluvialis holds very much
Easily by blood-brain barrier and cell membrane, it can be effectively prevented the oxidation of retina and the damage of photosensory cell, and to maincenter mind
It especially plays a protective role to brain through system, so that effectively treatment ischemia reperfusion injury, spinal cord injury, Parkinson are comprehensive
The central lesions such as simulator sickness, Alzheimer syndrome.
2, ultraviolet radiation preventing；Haematococcus pluvialis has special work to glutamine transaminage (transglutaminase)
With the strong anti-oxidation that can consume putrescine haematococcus pluvialis when skin is illuminated by the light may make it potential light protection
Agent effectively removes the free radical for causing skin aging, protects cell membrane and mitochondrial membrane from oxidative damage.
3, prevent cardiovascular disease；The clinical research of artery sclerosis and related cardiovascular disease shows low-density lipoprotein
(LDL) oxidation is to lead to the major reason of artery sclerosis.Haematococcus pluvialis mainly passes through: increase high-density lipoprotein HDL-C,
Low-density lipoprotein LDL is reduced to be oxidized to Ox-LDL, the formation for reducing atherosclerotic plaque, increase the steady of atherosclerotic plaque
Qualitative, reduction plaque rupture, improves the modes such as blood flow and carrys out prevention and cure of cardiovascular disease.
4, strengthen immunity；Haematococcus pluvialis can significantly affect the immune function of animal, can be obvious in the presence of having antigen
The ability for promoting splenocyte to generate antibody enhances the effect of T cell, stimulates the generation of vivo immunization globulin.Haematococcus pluvialis
The immunity system of aged mice can also partially be restored, wherein mouse intracorporal IgM, IgA and IgG can be made all to increase respectively
To 10mol/L, show to invade initial stage in antigen, it can enhance specific humoral immunity reaction.It is thus regarded that haematococcus pluvialis has
The activity of very strong inducing cell division, has important immunoregulation effect.
5, alleviate sports fatigue, enhancing human body energy metabolism；When body movement, muscle can discharge free radical, these freedom
If base is not handled in time by antioxidant, oxidative pressure will be generated, causes the damage of DOMS or musculature.Study table
Bright, haematococcus pluvialis can be used as a kind of oxidative damage effect that antioxidant inhibits free radical to body, increase muscle strength
With muscle tolerance, alleviate sports fatigue rapidly, mitigates the Delayed onset myalgia generated after strenuous exercise.
6, anti-inflammatory anti-infective characteristic；Arthralgia and arthritis are usually caused by oxidative damage caused by free radical.Rain is raw
The stronger anti-oxidation characteristics of haematococcus help to inhibit free radical, reduce its oxidative damage to joint.
7, inhibit tumour；Scientific research personnel proposes the anticancer mechanism of haematococcus pluvialis, it is believed that the stability of it and cell membrane
It is related with protein gene expression, cell-cell communication is adjusted by changing membrane stability and gene expression quantity, to improve
Intercellular balanced capacity maintains the normal function of cell.
8, inhibit diabetic nephropathy；Diabetes patient 70% can development be that nephrosis is damaged in 5 years, and haematococcus pluvialis is can be with
The substance of diabetogenous nephrosis disease damage is effectively prevented, haematococcus pluvialis, which mainly passes through, directly to be protected glomerular basement membrane, prevents because of height
The free radical that blood glucose generates destroys basilar memebrane；Further, it is also possible to fight the free radical of renal cells, glucose is protected
And the normal transport in renal tubular cell of phosphorus, to save ATP and Na+K+exchanging ATPase these important substances, it is ensured that renal blood flow
It is unaffected, reduce the generation of albuminuria.
Anti-oxidant dietary supplements provided by the present application, due to not only having comprising grape extract and haematococcus pluvialis
Good anti-oxidation function, moreover it is possible to a lot of other health-care efficacies is played, is taken for a long time, it is highly beneficial to health.
The above is only the preferred embodiment of the present invention, it is noted that those skilled in the art are come
It says, without departing from the technical principles of the invention, several improvements and modifications can also be made, these improvements and modifications are also answered
It is considered as protection scope of the present invention.
Claims (9)
1. a kind of anti-oxidant dietary supplements, which is characterized in that by weight, comprising:
6~12 parts of grape extract；4~8 parts of haematococcus pluvialis；Remaining is soft capsule prepared product；
Wherein, the grape extract refers to extracts isolated polyphenols from Grape Skin and/or seed；The soft capsule system
Standby object is for material needed for dietary supplements is prepared into soft capsule.
2. anti-oxidant dietary supplements according to claim 1, which is characterized in that the soft capsule prepared product includes flexible glue
Intracapsular tolerant and soft capsule prepares auxiliary material；The parts by weight of the soft capsule content are 25~40 parts；The soft capsule preparation
The parts by weight of auxiliary material are 450~580 parts.
3. anti-oxidant dietary supplements according to claim 2, which is characterized in that the soft capsule content includes natural
Vitamin E, beeswax and Seabuckthorn Oil, the parts by weight of the natural VE are 1.6 parts, and the parts by weight of the beeswax are 1.6 parts,
The parts by weight of the Seabuckthorn Oil are 24 parts；It includes gelatin, purified water, glycerol and red ferric oxide, institute that the soft capsule, which prepares auxiliary material,
The parts by weight for stating glue clearly are 200 parts, and the parts by weight of the purified water are 200 parts, and the parts by weight of the glycerol are 80 parts, described red
The parts by weight of iron oxide are 2 parts.
4. anti-oxidant dietary supplements according to claim 3, which is characterized in that by weight, comprising: grape extracts
8 parts of object；4.8 parts of haematococcus pluvialis；1.6 parts of natural VE；1.6 parts of beeswax；24 parts of Seabuckthorn Oil；200 parts of gelatin；Purified water
200 parts；80 parts of glycerol；2 parts of red ferric oxide.
5. a kind of anti-oxidant meal supplement agent and process for producing same as described in claim 3 or 4 characterized by comprising
Grape extract and haematococcus pluvialis are mixed, the first mixture is prepared into；
Natural VE, beeswax and Seabuckthorn Oil are mixed and are processed into oily wax liquor；
First mixture is mixed with oily wax liquor and is processed into filling liquid；
Gelatin, purified water, glycerol and red ferric oxide are mixed and are processed into glue；
Capsule pellet press is by filling liquid and glue machine-shaping.
6. anti-oxidant meal supplement agent and process for producing same according to claim 5, which is characterized in that by natural VE, bee
Wax and Seabuckthorn Oil mix and are processed into oily wax liquor
Natural VE and Seabuckthorn Oil are mixed and heated (heating temperature is 75-85 DEG C), are prepared into the second mixture；By second
Mixture and beeswax are mixed and heated (heating temperature is 70-80 DEG C), are prepared into oily wax liquor；After oily wax liquor cooling (40-50 DEG C)
It is mixed with the first mixture.
7. anti-oxidant meal supplement agent and process for producing same according to claim 5 or 6, which is characterized in that by the first mixture
It is mixed with oily wax liquor and is processed into filling liquid and include:
First mixture is mixed with oily wax liquor and is stirred in material-compound tank；It is ground after stirring；De-bubbled after grinding；It is prepared into filling
Liquid.
8. anti-oxidant meal supplement agent and process for producing same according to claim 5, which is characterized in that by gelatin, purified water, sweet
Oil and red ferric oxide, which mix and be processed into glue, includes:
Purified water and glycerol are mixed and heated (heating temperature is 70-80 DEG C), are prepared into third mixture；
Gelatin, red ferric oxide and third mixture are mixed and stirred for, realizationization glue；
De-bubbled is prepared into glue.
9. anti-oxidant meal supplement agent and process for producing same according to claim 5, which is characterized in that capsule pellet press will fill
Liquid and glue machine-shaping include:
Pellet is made in filling liquid and glue by capsule pellet press；Stand setting；Cleaning；It is dry；Quality inspection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811091498.1A CN109315770A (en) | 2018-09-19 | 2018-09-19 | Anti-oxidant dietary supplements and its production method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811091498.1A CN109315770A (en) | 2018-09-19 | 2018-09-19 | Anti-oxidant dietary supplements and its production method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109315770A true CN109315770A (en) | 2019-02-12 |
Family
ID=65266156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811091498.1A Pending CN109315770A (en) | 2018-09-19 | 2018-09-19 | Anti-oxidant dietary supplements and its production method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109315770A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113080453A (en) * | 2021-04-23 | 2021-07-09 | 江苏金维氨生物工程有限公司 | Preparation method of special dietary supplement |
| CN114190555A (en) * | 2021-12-18 | 2022-03-18 | 江苏艾兰得营养品有限公司 | Drop pills with antioxidation efficacy and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1742891A (en) * | 2005-05-11 | 2006-03-08 | 黑龙江九三油脂有限责任公司 | Fructus-Hippophae oil composite soft capsule |
| US20080171032A1 (en) * | 2007-01-12 | 2008-07-17 | Kelly Gregory J | Dietary supplement composition and method of use for the treatment and prevention of oxidative stress |
| CN103431401A (en) * | 2013-09-16 | 2013-12-11 | 厦门中药厂有限公司 | Antioxidant health care food and application thereof |
| CN103494202A (en) * | 2013-10-18 | 2014-01-08 | 济南老来寿生物股份有限公司 | Healthcare food with antioxidant function |
| CN108077936A (en) * | 2017-11-16 | 2018-05-29 | 山西五台山沙棘制品有限公司 | A kind of Seabuckthorn Oil Spirulina soft capsule and preparation method thereof |
-
2018
- 2018-09-19 CN CN201811091498.1A patent/CN109315770A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1742891A (en) * | 2005-05-11 | 2006-03-08 | 黑龙江九三油脂有限责任公司 | Fructus-Hippophae oil composite soft capsule |
| US20080171032A1 (en) * | 2007-01-12 | 2008-07-17 | Kelly Gregory J | Dietary supplement composition and method of use for the treatment and prevention of oxidative stress |
| CN103431401A (en) * | 2013-09-16 | 2013-12-11 | 厦门中药厂有限公司 | Antioxidant health care food and application thereof |
| CN103494202A (en) * | 2013-10-18 | 2014-01-08 | 济南老来寿生物股份有限公司 | Healthcare food with antioxidant function |
| CN108077936A (en) * | 2017-11-16 | 2018-05-29 | 山西五台山沙棘制品有限公司 | A kind of Seabuckthorn Oil Spirulina soft capsule and preparation method thereof |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113080453A (en) * | 2021-04-23 | 2021-07-09 | 江苏金维氨生物工程有限公司 | Preparation method of special dietary supplement |
| CN114190555A (en) * | 2021-12-18 | 2022-03-18 | 江苏艾兰得营养品有限公司 | Drop pills with antioxidation efficacy and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103637197A (en) | Propolis soft capsule and preparation method thereof | |
| CN103431392B (en) | Composite marine food for special dietary uses for diabetics | |
| KR101517095B1 (en) | Periodontal diseases treatment and prevention composition using the natural extracts | |
| CN109315770A (en) | Anti-oxidant dietary supplements and its production method | |
| JP2021508433A (en) | Carob fruit composition and its preparation method and application | |
| CN108391816A (en) | A kind of production method of antioxidant healthcare capsule | |
| CN112869073A (en) | Chinese medicinal composition comprising fruits and vegetables for improving human body function and removing harmful toxin, and its preparation method | |
| KR102003755B1 (en) | Germinated Fermented Soybean Extract Having Effect of Protecting Liver Cells and Increasing Bone Density Containing Coumesterol, And Composition Containing The Extract | |
| KR20110105627A (en) | Anti-obesity composition containing silkworm hemolymph | |
| CN116762954A (en) | Health food for improving immunity and preparation method thereof | |
| TW201006389A (en) | Formulations, methods and its use for reducing abdominal fat and waist circumference | |
| CN106509606A (en) | Cereals capable of recuperating constitutions of pregnant women and production technology of cereals | |
| KR101820944B1 (en) | Companion animal ophthalmology disease management assistance nutrient and the manufacture Method | |
| CN106174286A (en) | Senior gold Chinese-wolfberry nutritive fruit jam | |
| KR20080090808A (en) | Composition of healthy food for a skin | |
| KR20230038110A (en) | Composition for preventing, alleviating, or treating muscle weakness diseases comprising Setaria viridis extract as an active ingredient | |
| CN108371709A (en) | Lycium ruthenicum tumor recovering gene enzyme | |
| WO2014134834A1 (en) | Composition and food comprising same and preparation method of food | |
| CN102763759A (en) | Black garlic chewing gum | |
| CN106490604A (en) | A kind of anti-oxidant Green Tea Extract health care product and preparation method thereof | |
| KR101241455B1 (en) | Bean curd having hypotensive effect | |
| KR20170029764A (en) | Garlic extracts, egg yolk extracts and sulfur mixture to back out of the prevention of cardiovascular, cerebrovascular and other circulatory organ system disease, for the inclusion of active ingredients and treatment of functional foods, improvement and the manufacturing method. and Health functional food, organic sulphur (MSM)as active ingredients composition | |
| KR20200145745A (en) | Composition comprising steamed mature silkworm products having silk protein for preventing or treating obesity | |
| JPWO2008111651A1 (en) | Metabolic syndrome improving or preventing agent, and beverage, food and feed containing the same | |
| CN104958345A (en) | Soybean lecithin soft capsule with lipid-reducing function and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190212 |